1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY

Material: Gatifloxacin Ophthalmic Solution 0.5%

Manufacturer: Lupin Limited
Pithampur (M. P.), 454 775
India.

Distributor: Lupin Pharmaceuticals, Inc.
Harborplace Tower, 21st Floor
111, South Calvert Street
Baltimore, MD 21202
United States
Tel. 001-410-576-2000
Fax. 001-410-576-2221

2. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>CAS</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gatifloxacin</td>
<td>112811-59-3</td>
<td>0.5%</td>
</tr>
</tbody>
</table>

3. HAZARD IDENTIFICATION

Fire and Explosion: Expected to be non-combustible
Health: None
Environment: No information is available about the potential of this product to produce adverse environmental effects.

4. FIRST AID MEASURE

Ingestion: If conscious, give water to drink and induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical attention.


**6. ACCIDENTAL RELEASE MEASURES**

**Inhalation**
Move individual to fresh air. Obtain medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance.

**Skin Contact**
Remove contaminated clothing and flush exposed area with large amounts of water. Wash all exposed areas of skin with plenty of soap and water. Obtain medical attention if skin reaction occurs.

**Eye Contact**
Rinse immediately with copious amount of water for at least 20 minutes. Contact a physician.

**NOTES TO HEALTH PROFESSIONALS**

**Medical Treatment**
Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient’s airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient’s vital signs, blood gases, serum electrolytes, etc.

**5. FIRE FIGHTING MEASURE**

**Fire and Explosion Hazards**
Assume that this product is capable of sustaining combustion.

**Extinguishing Media**
Water spray, carbon dioxide, dry chemical powder or appropriate foam.

**Special Firefighting Procedures**
For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters.

**Hazardous Combustion Products**
Hazardous combustion or decomposition products are expected when the product is exposed to fire.

**6. ACCIDENTAL RELEASE MEASURES**

**Personal Precautions**
Wear protective clothing and equipment consistent with the degree of hazard.

**Environmental Precautions**
For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.

**Clean-up Methods**
Collect and place it in a suitable, properly labeled container for recovery or disposal.
7. HANDLING AND STORAGE

Handling
Avoid contact with the product and use caution to prevent puncturing containers. Normal room ventilation is expected to be adequate for routine handling of this product.

Storage
Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature]. Protect from freezing.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical Form
Gatifloxacin Ophthalmic Solution, 0.5% is supplied sterile in a 5 mL white, low density polyethylene bottle (LDPE) fitted with a white low density polyethylene (LDPE) nozzle and sealed with a tan colored high density polyethylene (HDPE) cap in the following size:

2.5 mL in 5 mL bottle: NDC 68180-435-01

10. STABILITY AND REACTIVITY

Stable under recommended storage conditions.

11. TOXICOLOGICAL INFORMATION

Carcinogenesis, Mutagenesis, Impairment of Fertility

There was no increase in neoplasms among B6C3F1 mice given gatifloxacin in the diet for 18 months at doses averaging 81 mg/kg/day in males and 90 mg/kg/day in females. These doses are approximately 1600-fold and 1800-fold higher, respectively, than the maximum recommended ophthalmic dose of 0.05 mg/kg/day in a 50 kg human.

There was no increase in neoplasms among Fischer 344 rats given gatifloxacin in the diet for 2 years at doses averaging 47 mg/kg/day in males and 139 mg/kg/day in females (900- and 2800-fold higher, respectively, than the maximum recommended ophthalmic dose). A statistically significant increase in the incidence of large granular lymphocyte (LGL) leukemia was seen in males treated with a high dose of approximately 2000-fold higher than the maximum recommended ophthalmic dose. Fischer 344 rats have a high spontaneous
background rate of LGL leukemia and the incidence in high-dose males only slightly exceeded the historical control range established for this strain.

In genetic toxicity tests, gatifloxacin was positive in 1 of 5 strains used in bacterial reverse mutation assays: Salmonella strain TA102. Gatifloxacin was positive in \textit{in vitro} mammalian cell mutation and chromosome aberration assays. Gatifloxacin was positive in \textit{in vitro} unscheduled DNA synthesis in rat hepatocytes but not human leukocytes. Gatifloxacin was negative in \textit{in vivo} micronucleus tests in mice, cytogenetics test in rats, and DNA repair test in rats. The findings may be due to the inhibitory effects of high concentrations on eukaryotic type II DNA topoisomerase.

There were no adverse effects on fertility or reproduction in rats given gatifloxacin orally at doses up to 200 mg/kg/day (approximately 4000-fold higher than the maximum recommended ophthalmic dose for gatifloxacin ophthalmic solution, 0.5%).

12. ECOLOGICAL INFORMATION

No relevant studies identified.

13. DISPOSAL CONSIDERATION

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

14. TRANSPORT INFORMATION

**IATA/ICAO - Not Regulated**
- IATA Proper shipping Name : N/A
- IATA UN/ID No : N/A
- IATA Hazard Class : N/A
- IATA Packaging Group : N/A
- IATA Label : N/A

**IMDG - Not Regulated**
- IMDG Proper shipping Name : N/A
- IMDG UN/ID No : N/A
- IMDG Hazard Class : N/A
- IMDG Flash Point : N/A
- IMDG Label : N/A
15. REGULATORY INFORMATION

This Section Contains Information relevant to compliance with other Federal and/or state laws.

16. OTHER INFORMATION

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this MSDS.